SSA
KYMR icon

Schonfeld Strategic Advisors’s Kymera Therapeutics KYMR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
+12,582
New +$996K 0.01% 1068
2025
Q4 		– Sell
-39,746
Closed -$2.25M – 2331
2025
Q3 		$2.25M Sell
39,746
-19,178
-33% -$865K 0.01% 973
2025
Q2 		$2.57M Buy
58,924
+10,764
+22% +$371K 0.02% 845
2025
Q1 		$1.32M Sell
48,160
-167,320
-78% -$6.1M 0.01% 1165
2024
Q4 		$8.67M Buy
215,480
+36,294
+20% +$1.64M 0.05% 336
2024
Q3 		$8.48M Sell
179,186
-110,277
-38% -$4.87M 0.06% 347
2024
Q2 		$8.64M Sell
289,463
-90,979
-24% -$3.15M 0.06% 390
2024
Q1 		$15.3M Sell
380,442
-57,191
-13% -$2.05M 0.1% 238
2023
Q4 		$11.1M Buy
+437,633
New +$7.83M 0.07% 316
2023
Q1 		– Sell
-17,400
Closed -$434K – 2373
2022
Q4 		$434K Buy
+17,400
New +$464K ﹤0.01% 1605
2020
Q4 		– Sell
-6,672
Closed -$216K – 1727
2020
Q3 		$216K Buy
+6,672
New +$204K ﹤0.01% 1200

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Schonfeld Strategic Advisors's KYMR Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Kymera Therapeutics (KYMR) in Q1 2026: 12,582 shares worth $1.05M. The stake represents 0.01% of the portfolio and ranks #1068 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in KYMR as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in KYMR in Q3 2020 and has held it in 11 quarters since. The position peaked at $15.3M in Q1 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Schonfeld Strategic Advisors held 12,582 shares of Kymera Therapeutics worth $1.05M as of Q1 2026.
  • Kymera Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Kymera Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1068 holding.
  • Schonfeld Strategic Advisors first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 11 quarters since.
  • Schonfeld Strategic Advisors's Kymera Therapeutics position peaked at $15.3M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.